"second line" trang 2 - tải miễn phí từ tailieuXANH
Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: A population-based cohort study in Ontario, Canada

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: A population-based cohort study in Ontario, Canada
10    56    0
Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: A systematic review and secondary analysis of trials

Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: A systematic review and secondary analysis of trials
17    48    0
The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: A prospective observational multicenter study protocol (IVY)

The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: A prospective observational multicenter study protocol (IVY)
6    34    0
Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: A systematic review and network meta-analysis

Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: A systematic review and network meta-analysis
16    57    0
Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer

Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer
9    76    0
Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: Data from a national registry

Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: Data from a national registry
8    82    0
Phase II trial of eribulin mesylate as a firstor second-line treatment for locally advanced or metastatic breast cancer: A multicenter, single-arm trial

Phase II trial of eribulin mesylate as a firstor second-line treatment for locally advanced or metastatic breast cancer: A multicenter, single-arm trial
7    92    0
Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing firstline gemcitabine-containing therapy: Effect of performance status and comparison with other regimens

Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing firstline gemcitabine-containing therapy: Effect of performance status and comparison with other regimens
9    89    0
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)
9    100    0
RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis

RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis
4    84    0
Erlotinib treatment after platinum-based therapy in elderly patients with non-smallcell lung cancer in routine clinical practice – results from the ElderTac study

Erlotinib treatment after platinum-based therapy in elderly patients with non-smallcell lung cancer in routine clinical practice – results from the ElderTac study
11    60    0
Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: A model-based economic evaluation

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: A model-based economic evaluation
11    56    0
A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer

A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer
10    70    0
Epicure: A European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy

Epicure: A European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy
9    50    0
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants
6    56    0
Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: A case report

Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: A case report
5    55    0
Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP)

Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP)
8    166    0
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
8    83    0
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer

A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer
7    57    0
Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice

Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice
9    46    0
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.